Image
Loading
Image
16 November, 2026

Genekor Medical at the 12th Panhellenic Congress of EXEM 2026 

Genekor Medical participated in the 12th Panhellenic Congress of the Hellenic Society of Breast Surgery (EXEM), held on November 13–15, 2026, with an active scientific presence and contributions to five research studies, while also supporting the congress as a Platinum Sponsor. 

The congress served as an important meeting point for the scientific community, focusing on the latest advances in breast cancer diagnostics, surgery, and personalized treatment approaches. 

Scientific Lecture: Oncotype DX® and the Latest Evidence in Treatment Decision-Making 

As part of the scientific program, Professor Emeritus Dr. Christos Markopoulos delivered a lecture entitled: 

“Oncotype DX® and Breast Cancer: Latest Evidence in Treatment Decision-Making.” 

  • Speaker: Professor Emeritus Dr. Christos Markopoulos 
  • Session Chair: Dr. Vasileios Venizelos 

The lecture focused on the latest scientific evidence regarding Oncotype DX® and its role in supporting evidence-based, personalized treatment decisions in breast cancer clinical practice. 

Scientific Contributions to Five Research Studies 

Genekor Medical also contributed to the scientific program through its participation in five research studies covering key aspects of molecular diagnostics, hereditary cancer predisposition, and the clinical application of genomic data. 

1. Multigene Testing in Healthy Individuals with a Family History of Breast and Ovarian Cancer: Clinical Experience in Cancer Prevention (Abstract 1414) 

The study was presented by Dr. Dimitra Bouzarelou, MSc, PhD, ErCLG, Clinical Laboratory Geneticist and Head of the Hereditary Diseases Department at Genekor Medical, highlighting clinical experience with the application of multigene testing in individuals with a family history of breast and ovarian cancer. 

2. Beyond Mutation Frequencies: Network-Based Characterization of Genomic Alteration Patterns in Breast Cancer (Abstract 1409) 

This study investigated patterns of genomic alterations in breast cancer using a network-based analytical approach, extending beyond the frequency of individual mutations. 

3. Oncotype DX® in Invasive Lobular Carcinoma: Distribution, Treatment Decisions, and Outcomes in 64 Patients (Abstract 1463) 

The study examined the distribution of Oncotype DX® results, treatment decisions, and clinical outcomes in 64 patients with invasive lobular breast carcinoma. 

4. Genomic Versus Clinical Risk in Early-Stage ER+/HER2− Breast Cancer: Analysis of 670 Patients Who Underwent Oncotype DX® Testing (Abstract 1465) 

This study focused on comparing genomic and clinical risk through the analysis of data from 670 patients with early-stage breast cancer. 

5. Retrospective Analysis of Oncotype DX Recurrence Score® Results in Core Needle Biopsy Specimens (Abstract 1397) 

The study focused on evaluating Oncotype DX Recurrence Score results in core needle biopsy specimens from patients with early-stage ER+/HER2− breast cancer. 

Together, these research studies highlighted different applications of genomic testing and its importance in supporting contemporary clinical practice. 

Supporting the Scientific Community as a Platinum Sponsor 

As a Platinum Sponsor of the 12th Panhellenic Congress of EXEM, Genekor Medical actively supported the breast surgery community, contributing to scientific knowledge exchange and highlighting the latest advances in molecular diagnostics and precision medicine. 

Through collaboration with healthcare professionals and participation in research initiatives, Genekor Medical continues to contribute to the advancement and application of precision medicine, supporting personalized treatment decisions. 

It was a pleasure meeting everyone at the congress and exchanging valuable scientific insights and experiences.